ELUXADOLINE | A213511 | AUROBINDO PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Allergan USA, Inc., et al. v. MSN Laboratories Private Limited, et al. 6 patentsANDA 213511, 213613, 213427, 213576, 213447, 213522eluxadoline | D. Del. | 2019-09-13 | Terminated 2025-01-02 | — |
| D. Del. | 2019-09-06 | Terminated 2022-02-09 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.
Aurobindo Pharma received FDA approval for eluxadoline (ANDA 213511, Supplement 002).
New: New record
Aurobindo Pharma's ANDA for eluxadoline (NDA 213511, supplement 001) was added to the FDA products database.
New: New record